安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2014年
10期
1968-1970
,共3页
沐舒坦%慢性阻塞性肺病%肺功能
沐舒坦%慢性阻塞性肺病%肺功能
목서탄%만성조새성폐병%폐공능
ambroxol%chronic obstructive pulmonary disease%lung function
目的:探讨不同剂量沐舒坦对改善急性加重期慢性阻塞性肺病(AECOPD)患者肺功能的效果。方法将102例AECO-PD患者随机分为3组,分别为对照组32例:给予支气管扩张剂、常规吸氧及抗生素静脉滴注治疗,7 d为1疗程;沐舒坦常规剂量组35例:在对照组的基础上给予剂量为30 mg/次沐舒坦静脉滴注治疗,每天3次,7 d为1疗程;沐舒坦大剂量组35例:在对照组的基础上给予剂量为150 mg/次沐舒坦静脉滴注,每天2次,7 d为1疗程。对比分析三组治疗前后肺功能指标、血气指标及总有效率。结果三组患者治疗后肺功能指标均得到改善,其中大剂量组治疗后FEV1.0、PEF 以及FEV1.0/FVC、6MWD水平显著高于常规剂量组及对照组,两两比较有统计学意义(P<0.05)。大剂量组治疗后SaO2、PaO2、PaO2/FiO2水平显著高于常规剂量组及对照组,两两比较差异有统计学意义(P<0.05)。大剂量组总有效率为94.28%,常规剂量组总有效率为82.86%,对照组总有率为78.13%,两两比较差异有统计学意义(P<0.05)。大剂量组不良反应4例(11.43%),常规剂量组不良反应3例(9.37%),对照组不良反应2例(6.25%),不良反应率两两比较无统计学差异。结论大剂量沐舒坦能有效改善AECOPD患者肺功能指标及血气指标,疗效显著,不良反应率低。
目的:探討不同劑量沐舒坦對改善急性加重期慢性阻塞性肺病(AECOPD)患者肺功能的效果。方法將102例AECO-PD患者隨機分為3組,分彆為對照組32例:給予支氣管擴張劑、常規吸氧及抗生素靜脈滴註治療,7 d為1療程;沐舒坦常規劑量組35例:在對照組的基礎上給予劑量為30 mg/次沐舒坦靜脈滴註治療,每天3次,7 d為1療程;沐舒坦大劑量組35例:在對照組的基礎上給予劑量為150 mg/次沐舒坦靜脈滴註,每天2次,7 d為1療程。對比分析三組治療前後肺功能指標、血氣指標及總有效率。結果三組患者治療後肺功能指標均得到改善,其中大劑量組治療後FEV1.0、PEF 以及FEV1.0/FVC、6MWD水平顯著高于常規劑量組及對照組,兩兩比較有統計學意義(P<0.05)。大劑量組治療後SaO2、PaO2、PaO2/FiO2水平顯著高于常規劑量組及對照組,兩兩比較差異有統計學意義(P<0.05)。大劑量組總有效率為94.28%,常規劑量組總有效率為82.86%,對照組總有率為78.13%,兩兩比較差異有統計學意義(P<0.05)。大劑量組不良反應4例(11.43%),常規劑量組不良反應3例(9.37%),對照組不良反應2例(6.25%),不良反應率兩兩比較無統計學差異。結論大劑量沐舒坦能有效改善AECOPD患者肺功能指標及血氣指標,療效顯著,不良反應率低。
목적:탐토불동제량목서탄대개선급성가중기만성조새성폐병(AECOPD)환자폐공능적효과。방법장102례AECO-PD환자수궤분위3조,분별위대조조32례:급여지기관확장제、상규흡양급항생소정맥적주치료,7 d위1료정;목서탄상규제량조35례:재대조조적기출상급여제량위30 mg/차목서탄정맥적주치료,매천3차,7 d위1료정;목서탄대제량조35례:재대조조적기출상급여제량위150 mg/차목서탄정맥적주,매천2차,7 d위1료정。대비분석삼조치료전후폐공능지표、혈기지표급총유효솔。결과삼조환자치료후폐공능지표균득도개선,기중대제량조치료후FEV1.0、PEF 이급FEV1.0/FVC、6MWD수평현저고우상규제량조급대조조,량량비교유통계학의의(P<0.05)。대제량조치료후SaO2、PaO2、PaO2/FiO2수평현저고우상규제량조급대조조,량량비교차이유통계학의의(P<0.05)。대제량조총유효솔위94.28%,상규제량조총유효솔위82.86%,대조조총유솔위78.13%,량량비교차이유통계학의의(P<0.05)。대제량조불량반응4례(11.43%),상규제량조불량반응3례(9.37%),대조조불량반응2례(6.25%),불량반응솔량량비교무통계학차이。결론대제량목서탄능유효개선AECOPD환자폐공능지표급혈기지표,료효현저,불량반응솔저。
Objective To investigate the effects of different doses of ambroxol on lung function of patients with acute exacerbation ofchronic obstructive pulmonary disease (AECOPD).Methods A hundred and two cases of AECOPD patients were randomly assignedinto control group(n =32),treated with bronchodilators,conventional oxygen and intravenous antibiotic therapy for 7 d,mucosolvan con-ventional-dose group(n =35),treated with mucosolvan intravenous infusion therapy(3 times/d)for 7 d,and mucosolvan high dosegroup(n =35),treated with 150 mg/times mucosolvan(2 times/d)for 7 d.The total effective rate,lung functions and blood indices ofthree groups before and after treatment were compared.Results Lung functions of all three groups were improved after treatment.Thelevels of FEV1.0 %,PEF% and FEV1.0 /FVC,6MWD of high-dose group were higher than the conventional dose group and the controlgroup (P <0.05).The levels of SaO2 ,PaO2 ,PaO2 /FiO2 of high-dose group were higher than the conventional dose group and the con-trol group after the treatment(P <0.05).The total effective rates of high-dose group,conventional dose group and control group were94.28%,82.86% and 78.13%,respectively(P <0.05).There were 4 cases (11.43%),3 cases (9.37%),and 2 cases (6.25%)of adverse reactions in high-dose group,conventional dose group and control group,respectively.The adverse reaction rates were not sta-tistically significant(P >0.05).Conclusions High-dose ambroxol can effectively improve lung function and blood gas in patients withAECOPD,which achieves significant effects with less adverse reactions.